PACTR201512001069358已完成2 期
A Randomized, Placebo Controlled, Partially Blinded Phase II Study to Evaluate Safety, Immunogenicity, and Prevention of Infection With Mycobacterium Tuberculosis of AERAS-404 and BCG Revaccination in Healthy Adolescents
Aeras0 个研究点目标入组 990 人开始时间: 2015年3月12日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 990
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 12 Year(s) 至 17 Year(s)（—）
- 性别
- All
入选标准
- •1.Has completed the written informed consent and assent process
- •2.Is age ¿ 12 years and ¿ 17 years on Study Day 0
- •3.Agrees to stay in contact with the study site for the duration of the study, provide updated contact information
- •4.For female subjects: agrees to avoid pregnancy from 28 days prior to Study Day 0 and for the full duration of the study.
- •5.Has general good health, confirmed by medical history and physical examination
- •6.Has body mass index (BMI) for age and sex between the 5th and 95th centiles by Centers for Disease Control nomogram
- •7.Had BCG vaccination at least 5 years ago documented through medical history or by presence of healed BCG scar
- •8.Tests QFT-GIT negative at screening, using the manufacturer's recommended threshold of 0.35 IU/m
排除标准
- •1.Acute illness on Study Day 0
- •2.Oral temperature <=37.5°C on Study Day 0
- •3.Clinically significant (and no more than Grade 1 on the Toxicity Scale) abnormal laboratory values from blood collected within 21 days
- •4.Evidence of clinically significant (and no more than Grade 1 on the Toxicity Scale) systemic or local disease on urinalysis
- •5.History or evidence of any clinically significant systemic disease, or any acute or chronic illness that might affect the safety, immunogenicity, or efficacy of study vaccine in the opinion of the investigator
- •6.History of treatment for active TB disease or latent Mtb infection
- •7.History or evidence, including chest X-ray, of active TB disease
- •8.Shared residence with an individual receiving anti-TB treatment, or known incompletely treated culture or smear positive TB
- •9.History of autoimmune disease or immunosuppression
- •10.Used immunosuppressive medication within 42 days before Study Day 0
- •11.Received immunoglobulin or blood products within 42 days before Study Day 0
- •12.Received any investigational drug therapy or investigational vaccine within 182 days before Study Day 0
- •13.Received investigational TB vaccine, other than BCG
- •14.Planned administration/administration of a licensed vaccine in the period starting 28 days before and ending 28 days after each dose of study vaccine
- •15.History or laboratory evidence of any past or present possible immunodeficiency state not limited to any lab indication of HIV-1 infection
- •16.History of allergic disease likely to be exacerbated by any component of the study vaccine
- •17.History of alcohol or drug abuse
- •18.All female subjects: currently pregnant or lactating/nursing; or positive urine pregnancy test during screening
- •19.Received a (TST) within 3 months (90 days) prior to Study Day 0.
- •20.Any current medical, psychiatric, occupational, substance abuse problems problems that in opinion of investigator will make unlikely for the subject to comply with the protocol
研究者
相似试验
已完成
不适用
A pilot study to investigate the effects of short course oral corticosteroid therapy in early dengue infection in Vietnamese patientsInfections and InfestationsDengue fever [classical dengue]Dengue feverISRCTN39575233niversity of Oxford (UK)225
进行中（未招募）
1 期
Study of efficacy and safety of VAY736 in patients with relapsing-remitting multiple sclerosisEUCTR2013-002324-16-PLovartis Pharma Services AG96
进行中（未招募）
1 期
Study of efficacy and safety of VAY736 in patients with relapsing-remitting multiple sclerosisrelapsing-remitting multiple sclerosisMedDRA version: 17.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2013-002324-16-CZovartis Pharma Services AG96
已完成
不适用
A Blinded, Placebo-Controlled, Randomized, Single Ascending Dose Study in Healthy Male Subjects to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-37822681psychosis10039628NL-OMON30850Johnson & Johnson Pharmaceutical24
进行中（未招募）
1 期
Avexxin (AVX001) 3% Ointment (NG) in Atopic Dermatitis – safety and efficacy studyEUCTR2016-003013-96-DKAvexxin AS